Dmvm Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.25 Cr
- Paid Up Capital ₹ 2.21 Cr
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -59.60%
- Profit Growth 117.02%
- Ebitda -1.92%
- Net Worth 2.98%
- Total Assets 12.69%
About Dmvm Drugs
Dmvm Drugs Private Limited (DDPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 October 2019 (Five years and three months 26 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.25 Cr and a paid-up capital of Rs 2.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Molina Dev and Nitish Dev serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24297DL2019PTC356003
-
Company No.
356003
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Oct 2019
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Dmvm Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Molina Dev
|
Director | 09-Oct-2019 | Current |
|
Nitish Dev
|
Additional Director | 30-Apr-2024 | Current |
Financial Performance of Dmvm Drugs.
Dmvm Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59.6% decrease. The company also saw a substantial improvement in profitability, with a 117.02% increase in profit. The company's net worth moved up by a moderate rise of 2.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dmvm Drugs?
In 2023, Dmvm Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Njd Spices Private LimitedMolina Dev is a mutual person
-
Njd Ayurvedic Products Private Limited
Molina Dev is a mutual person
-
Devpriya Polymers Private Limited
Molina Dev and Nitish Dev are mutual person
-
Njd Polymers Private Limited
Molina Dev is a mutual person
-
Kpmn Polymers Private Limited
Molina Dev is a mutual person
-
Dev Infrastructure Private Limited
Molina Dev and Nitish Dev are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dmvm Drugs?
Unlock and access historical data on people associated with Dmvm Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dmvm Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dmvm Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
